Business Wire · Dec 2025
Reported NSCLC validation data across 1,487 samples and positioned OncoPrism-NSCLC as a predictive biomarker for ICI benefit.
Cofactor closes the precision medicine gap with predictive diagnostics
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Cofactor Genomics is a commercial-stage biotechnology company focused on RNA-based predictive diagnostics for oncology, especially predicting patient response to immunotherapy. Its flagship product is OncoPrism, a machine-learning/RNA assay used in the PREDAPT clinical program and supported by CAP/CLIA laboratory operations.
Primary product
OncoPrism immunotherapy-response diagnostic
Founded
2015
Headquarters
St. Louis, Missouri, United States
Team size
1-10
Industry
Biotechnology
Sub-industry
Oncology diagnostics
Offices
St. Louis, Missouri, United States
Open Positions
0 jobs at Cofactor Genomics
No open positions
Check back later for new openings